1. Home
  2. Directory
  3. Washington
  4. Spokane
  5. Pharmacist
  6. NPI Profile
  7. Prescriptions 1992258404

SHURRIE MORRIS
Prescription History 1992258404
Pharmacist - Ambulatory Care in Spokane, WA

NPI Status: Active since August 02, 2016

Contact Information

46 E ROWAN AVE
SPOKANE, WA
ZIP 99207
Phone: (509) 482-3057

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SHURRIE MORRIS, an active Ambulatory Care specialist practicing in Spokane, WA. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 311 documented patient claims. Among these therapy options, the most frequently utilized medication is Warfarin Sodium, which accounts for 117 claims alone.

Medication Index

Aubagio

Generic Formulation: TeriflunomideSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
WA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.2
Peer Average Days Supply875
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $113,669.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,472.47

State Avg Cost Per Claim

$10,201.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used by adults to treat multiple sclerosis-MS. It is not a cure for MS but is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in your brain and spinal cord. This helps decrease the number of flare-ups (relapses) and may help slow down physical problems caused by MS.

Dimethyl Fumarate

Generic Formulation: Dimethyl FumarateSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 780
WA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply940
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,225.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$777.89

State Avg Cost Per Claim

$1,312.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fumarate derivative that is used as a DERMATOLOGIC AGENT in the treatment of PSORIASIS and SKIN DISEASES. It also may be used as an IMMUNOSUPPRESSIVE AGENT in the treatment of MULTIPLE SCLEROSIS.

Therapeutic Applications

Dimethyl fumarate is used to treat multiple sclerosis (MS). It is not a cure for MS. It helps decrease the number of episodes of worsening MS.

Eliquis

Generic Formulation: ApixabanSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 41
30-Day Fills 63.0
Days Supply 1,847
WA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills103.0
Peer Average Days Supply2,971
Conservative Utilization

This provider writes prescriptions for this formulation 29.3% less frequently than the standard regional baseline metric for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,773.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$823.75

State Avg Cost Per Claim

$929.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Enoxaparin Sodium

Generic Formulation: Enoxaparin SodiumSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 132
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.2
Peer Average Days Supply301
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,019.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$118.82

State Avg Cost Per Claim

$206.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a blood thinner. It is a type of heparin. Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other blood thinners.

Humira Pen

Generic Formulation: AdalimumabSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
WA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.9
Peer Average Days Supply586
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $142,617.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,970.58

State Avg Cost Per Claim

$7,833.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Therapeutic Applications

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

Kesimpta Pen

Generic Formulation: OfatumumabSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.4
Days Supply 842
WA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.1
Peer Average Days Supply680
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.3% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $276,049.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,858.91

State Avg Cost Per Claim

$9,196.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ofatumumab is used to treat a certain type of cancer (chronic lymphocytic leukemia - CLL). Ofatumumab belongs to a class of drugs known as monoclonal antibodies. This medication works by stopping the growth of cancer cells.

Mayzent

Generic Formulation: SiponimodSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 455
WA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.0
Peer Average Days Supply540
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $153,610.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,600.65

State Avg Cost Per Claim

$9,322.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of multiple sclerosis (relapsing multiple sclerosis-MS). Siponimod is not a cure for MS but it is thought to help by preventing immune system cells (lymphocytes) from attacking the nerves in your brain and spinal cord. It helps decrease the number of episodes of disease worsening (relapses) and may prevent or delay disability.

Stelara

Generic Formulation: UstekinumabSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 30
30-Day Fills 38.7
Days Supply 1,120
WA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills32.7
Peer Average Days Supply956
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.9% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $777,633.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$25,921.12

State Avg Cost Per Claim

$26,181.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Therapeutic Applications

Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative colitis). It works by blocking certain natural proteins in your body (interleukin-12 and interleukin-23) that cause inflammation (swelling) in these conditions. Ustekinumab does not cure these diseases, but helps to lessen symptoms of the disease. It can help to decrease the amount of plaques in plaque psoriasis, decrease the number of swollen/painful joints in psoriatic arthritis, and decrease symptoms such as abdominal pain/cramping and diarrhea in Crohn's disease and ulcerative colitis.

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 117
30-Day Fills 217.7
Days Supply 5,455
WA State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills128.4
Peer Average Days Supply3,610
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 98.3% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,833.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.67

State Avg Cost Per Claim

$16.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Xeljanz

Generic Formulation: Tofacitinib CitrateSpecialty: Pharmacist
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
WA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills24.1
Peer Average Days Supply723
Conservative Utilization

This provider writes prescriptions for this formulation 47.6% less frequently than the standard regional baseline metric for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $59,200.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,381.89

State Avg Cost Per Claim

$5,098.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tofacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis-pcJIA). It helps to decrease pain/tenderness/swelling in the joints. Tofacitinib is also used to treat a certain bowel disease (ulcerative colitis). It helps to reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SHURRIE MORRIS provides transparency into local medical care patterns within Spokane, WA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ambulatory Care** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.